Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 21, 2026
New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
View original at finance.yahoo.comNew Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026 REDMOND, Wash., May 21, 2026 /PRNewswire/ -- SystImmune, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
SystImmune's platform advances reinforce its ability to rapidly translate innovative science into differentiated therapies for patients with high unmet need worldwide
60% confidenceSystImmune is demonstrating both the clinical potential and scalability of its ADC platform through randomized Phase III trials of iza-bren and emerging proof-of-concept data across next-generation ADC programs
60% confidenceIza-bren is a potentially first-in-class EGFRxHER3 bispecific ADC
60% confidenceThe data presented at ASCO 2026 mark an important inflection point for SystImmune, with multiple late-stage readouts alongside continued expansion of the earlier pipeline
60% confidence